VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32173241/

⇱ Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
πŸ‘ Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

πŸ‘ Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.

Keywords: 2019-nCoV; Acute respiratory disease; Asymptomatic carrier; COVID-19; Coronavirus; SARS-CoV-2; Wuhan pneumonia.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The author declares no conflict of interests.

References

    1. WHO. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... [Accessed on 21 February 2020].
    1. Lee P.I., Hsueh P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53:365–367. doi: 10.1016/j.jmii.2020.02.001. - DOI - PMC - PubMed
    1. Huang W.H., Teng L.C., Yeh T.K., Chen Y.J., Lo W.J., Wu M.J. 2019 novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2020;53:481–484. doi: 10.1016/j.jmii.2020.02.009. - DOI - PMC - PubMed
    1. Liu Y.C., Liao C.H., Chang C.F., Chou C.C., Lin Y.R. A locally transmitted case of SARS-CoV-2 infection in Taiwan. N Engl J Med. 2020 Feb 12 doi: 10.1056/NEJMc2001573. - DOI - PMC - PubMed
    1. Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A. 2020. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. 2020.02.07.937862.
Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.